SCHEMBL29939613

SCHEMBL29939613

CCOC(=O)c1c(-c2ccc(OC(C)C)cc2F)nn2cccnc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.42
PRKCZ Q05513 1/20 0.39
TGFBR1 P36897 2/20 0.36
LMNA P02545 2/20 0.36
SLC34A1 Q06495 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3R1 P27986 1/20 0.35
PIK3CG P48736 1/20 0.35
ALDH1A1 P00352 3/20 0.35
KCNQ3 O43525 2/20 0.35
KCNQ2 O43526 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 2/20 0.35
CYP1A2 P05177 1/20 0.35
GLA P06280 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30029164 0.90 PRKCZ (0.49) PDE2APRKCZTGFBR1LMNASLC34A1
SCHEMBL29939370 0.87 SLC34A1 (0.45) PDE2ATGFBR1LMNASLC34A1PIK3CD
SCHEMBL27230014 0.87 PDE2A (0.42) PDE2ATGFBR1LMNASLC34A1PIK3CD
SCHEMBL27230012 0.86 ALOX5 (0.41) PDE2ATGFBR1LMNASLC34A1ALDH1A1
SCHEMBL29939653 0.85 MAPT (0.40) PDE2APRKCZTGFBR1LMNASLC34A1
SCHEMBL29939563 0.84 JAK2 (0.47) PDE2ATGFBR1LMNAALDH1A1MAPT
SCHEMBL27230050 0.84 KDM4E (0.38) PDE2ATGFBR1LMNASLC34A1PIK3CD
SCHEMBL30988102 0.83 PTGS2 (0.46) PDE2ATGFBR1LMNASLC34A1PIK3CD
SCHEMBL30988108 0.83 KCNQ3 (0.39) PDE2ATGFBR1LMNASLC34A1ALDH1A1
SCHEMBL27230048 0.83 PTGS2 (0.40) PDE2ATGFBR1LMNASLC34A1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12227507-B2 Pharmaceutical compounds PFIZER INC. (US) 2025-02-18 US disclosed
US-11634425-B2 Pharmaceutical compounds PFIZER INC. (US) 2023-04-25 US disclosed
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-10-13 US disclosed
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12227507-B2 Pharmaceutical compounds CHRNA6, GABRA6, CHRNA7 PDE2A 4652/4885PRKCZ 3918/4885TGFBR1 858/4885
US-11634425-B2 Pharmaceutical compounds GABRA6, CHRNA6, CNR1 PDE2A 4484/4885PRKCZ 4244/4885TGFBR1 954/4885
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS CHRNA6, GABRA6, CHRNA7 PDE2A 4652/4885PRKCZ 3918/4885TGFBR1 858/4885
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS GABRA6, CNR1, CHRNA6 PDE2A 4480/4885PRKCZ 4278/4885TGFBR1 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.